Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide

Biochemical and Biophysical Research Communications

Volumn 306, Issue 2, 2003, Pages 388-393

  Ridley, John M ^a   Milnes, James T ^a   Benest, Andrew V ^a   Masters, Joe D ^a   Witchel, Harry J ^a   Hancox, Jules C ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

Author keywords

Class Ia antiarrhythmic; Delayed rectifier; Disopyramide; HERG; K+ channel; Long QT syndrome; Procainamide; Quinidine

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; QUINIDINE;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; IC 50; MEMBRANE POTENTIAL; PATCH CLAMP; PRIORITY JOURNAL; RECOMBINANT GENE; TEMPERATURE;

EID: 0037870401     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00980-X     Document Type: Article

References (27)

1. Kr potassium channel. Cell. 81:1995;299.
2. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, an inward rectifier in the voltage-gated potassium channel family. Science. 269:1995;92-95.
3. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:1995;795-803.
4. Sanguinetti M.C., Curran M.E., Spector P.S., Keating M.S. Spectrum of HERG K channel dysfunction in an inherited cardiac arrhythmia. Proc. Natl. Acad. Sci. USA. 93:1996;2208-2212.
5. Witchel H.J., Hancox J.C. Congenital and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium channel. Clin. Exp. Pharmacol. Physiol. 27:2000;753-766.
6. + channels: friend and foe. TIPS. 22:2001;240-246.
7. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today. 2:1999;270-280.
8. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., Shah R. Special article: the potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovas. Res. 47:2000;219-233.
9. Kim S.Y., Benowitz N.L. Poisoning due to class Ia antiarrhythmic drugs: quinidine, procainamide and disopyramide. Drug Safety. 5:1990;393-420.
10. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
11. Lewis T. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction. Am. J. Med. Sci. 163:1922;781-794.
12. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation. 93:1996;407-411.
13. o dependence of the rapid component of the delayed rectifier K current in cardiac cells. Circ. Res. 80:1997;782-789.
14. Po S.S., Wang D.W., Yang I.C.H., Johnson J.P., Nie L., Bennett P.B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J. Cardiovasc. Pharmacol. 33:1998;181-185.
15. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 57:2000;367-374.
16. Ishii K., Kondo K., Takahashi M., Kimura M., Endoh M. An amino acid residue whose change by mutation affects drug binding to the HERG channel. FEBS Lett. 506:2001;191-195.
17. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. 136:2002;717-729.
18. Lima J.J., Boudoulas H. Stereoselective effects of disopyramide enantiomers in humans. J. Cardiovasc. Pharmacol. 9:1987;594-600.
19. Virag L., Varro A., Papp J.G. Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;268-275.
20. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. 280:2001;1243-1250.
21. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur. Heart J. 14:1993;88-92.
22. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., Priori S.G., Roden D.M., George A.L., Goldstein S.A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA. 97:2000;10613-10618.
23. Kr: model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol. 38:2001;737-744.
24. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 74:1998;230-241.
25. Drugs for cardiac arrhythmias. Med. Lett. Drugs Therapeutics 38 (1996) 75-82.
26. Thomas D., Gut B., Wendt-Nordahl G., Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go related gene (HERG) potassium channels. J. Pharm. Exp. Ther. 300:2002;534-548.
27. Weerapura M., Hebert T.E., Nattel S. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflügers Arch. 443:2002;520-531.